Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study

doi:10.4240/wjgs.v14.i9.904

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4729)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

209

WORD

HTML

2333

Figures (1-1)

213

Tables (1-3)

226

Sum=3049

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

324

Download

1356

Sum=1680

Sep 27, 2022 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Sep 27, 2022; 14(9): 904-917
Published online Sep 27, 2022. doi: 10.4240/wjgs.v14.i9.904

Open in New Tab Full Size Figure Download Figure

Figure 1 Overall survival and progression-free survival of patients treated with irinotecan or oxaliplatin before and after propensity score matching. A: Overall survival (OS) of patients treated with irinotecan or oxaliplatin before propensity score matching (PSM) by the Kaplan-Meier method; B: Progression-free survival (PFS) of patients treated with irinotecan or oxaliplatin before PSM by the Kaplan-Meier method; C: OS of patients treated with irinotecan or oxaliplatin after PSM by the Kaplan-Meier method; D: PFS of patients treated with irinotecan or oxaliplatin after PSM by the Kaplan-Meier method. OS: Overall survival; PFS: Progression-free survival; PSM: Propensity score matching.

Citation: Liu W, Chen FL, Wang K, Bao Q, Wang HW, Jin KM, Xing BC. Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study. World J Gastrointest Surg 2022; 14(9): 904-917
URL: https://www.wjgnet.com/1948-9366/full/v14/i9/904.htm
DOI: https://dx.doi.org/10.4240/wjgs.v14.i9.904